Cmed Opens New Offices in Durham, North Carolina

Cmed Opens New Offices in Durham, North Carolina

HORSHAM, England--(BUSINESS WIRE)-- To meet the needs of our customers and our growing business, Cmed Inc is delighted to announce the opening of its second US office in Durham, North Carolina.

David Connelly, CEO of Cmed, said, "We are very excited about establishing a second US base and our new offices in Durham, close to Research Triangle Park (RTP), are the perfect location for Cmed. RTP continues to be a model for innovation, education, and economic development and our new offices will allow us to draw on the tremendously skilled workforce in the Raleigh-Durham-Chapel Hill area, and to get close to our customers to provide even better service.

Our priority will be to build our Biostatistics team, but we will also continue to grow our Clinical and Data Management capabilities in line with our customers' needs. The goal is to establish a true ‘state of the art', integrated clinical operations group providing clinical, data management and biostatistics services around our sophisticated Timaeus technology. This will enable Cmed to offer genuinely cost effective services even in such operationally challenging areas as Adaptive Trial Design and the complexities of oncology."

Cmed established its first US foothold in 2001 with offices in New Providence, New Jersey, before quickly moving to a larger office in Murray Hill, New Jersey.

NOTES TO EDITORS:

About Cmed - Established in 2000, Cmed is an eCRO with offices in Horsham, UK, New Jersey and North Carolina USA and Timisoara, Romania. Cmed is a powerful combination of a full service CRO serving clients globally and a technology provision company which combines innovative data collection and management technology, using our proprietary Timaeus eDC/eDM system, with a smarter approach to delivering research services.

Our Timaeus technology and vast in-house experience enables us to provide services across a wide range of therapeutic areas and challenging geographical locations, covering clinical data management, project management, clinical monitoring and biostatistical services.


 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.